Division of Research Grants; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meeting:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Clinical Sciences.

Date: March 8, 1996.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4108, Telephone Conference.

Contact Person: Dr. Jules Selden, Scientific Review Administrator, 6701 Rockledge Drive, Room 4108, Bethesda, Maryland 20892, (301) 435–1785.

This notice is being published less than 15 days prior to the above meeting due to the partial shutdown of the Federal Government and the urgent need to meet timing limitations imposed by the grant review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.889, 93.893, National Institutes of Health, HHS).

Dated: March 6, 1996.

Susan K. Feldman,
Committee Management Officer, NIH.

[FR Doc. 96–5798 Filed 3–11–96; 8:45 am]

FOR FURTHER INFORMATION CONTACT:
Additional information can be obtained from Dr. Nelson A. Wivel, Director, Office of Recombinant DNA Activities (ORDA), Office of Science Policy, National Institutes of Health, MSC 7010, 6000 Executive Boulevard, Suite 302, Bethesda, Maryland 20892–7010, (301) 496–9838.

SUPPLEMENTARY INFORMATION: Today's action is being promulgated under the NIH Guidelines for Research Involving Recombinant DNA Molecules. This proposed action was published for comment in the Federal Register of November 15, 1995 (60 FR 57528), and reviewed and recommended for approval by the NIH Recombinant DNA Advisory Committee (RAC) at its meeting on December 4–5, 1995.

I. Background Information

SUMMARY: This notice sets forth an action to be taken by the Director, National Institutes of Health (NIH), under the NIH Guidelines for Research Involving Recombinant DNA Molecules.

II. Summary of Actions

A. Amendments to Section IV–B–4–e, Responsibilities of the Principal Investigator During the Conduct of the Research

Section IV–B–4–e(5) is amended to read:

"Section IV–B–4–e(5). Comply with annual data reporting and adverse event reporting requirements for NIH-and FDA-approved human gene transfer experiments (see Appendix M–VIII, Reporting Requirements—Human Gene Transfer Protocols)."

B. Amendments to Section IV–C–3, Responsibilities of the Office of Recombinant DNA Activities

Section IV–C–3–c is amended to read:

"Section IV–C–3–c. Administering the annual data reporting requirements (and subsequent review) for human gene transfer experiments, including experiments that are reviewed solely by the FDA (see Appendix M–VI, Categories of Human Gene Transfer Experiments that May Be Exempt from RAC Review)."

C. Amendments to Appendix M–VII, Categories of Human Gene Transfer Experiments That May Be Exempt for RAC Review

Appendix M–VII is amended to read:

"Appendix M–VII. Categories of Human Gene Transfer Experiments that May Be Exempt from RAC Review.

"A proposed submitted under one of the following categories may be considered exempt from RAC review unless otherwise determined by NIH/ORDA and the FDA on a case-by-case basis (see Appendix M–VI–A, Categories of Human Gene Transfer Experiments that Require RAC Review).

"Note: For proposals that are exempt from RAC review, the documentation described in Appendices M–I through M–V will be maintained by NIH/ORDA for compliance with annual data reporting and adverse event reporting requirements (see Appendix M–VIII, Reporting Requirements—Human Gene Transfer Protocols). Any subsequent modifications to proposals that were not reviewed by the RAC must be submitted to NIH/ORDA in order to facilitate data reporting requirements.

D. Amendments to Appendix M–VIII, Reporting Requirements—Human Gene Transfer Protocols

Appendix M–VIII–A is amended to read:

"Appendix M–VIII–A Annual Data Reporting

"Inventors who have received approval from the FDA to initiate a human gene transfer protocol (whether or not it has been reviewed by the RAC) shall be required to comply with the annual data reporting..."
requirements. Annual Data Report forms will be forwarded by NIH/ORDA to investigators. Data submitted in these reports will be evaluated by the RAC, NIH/ORDA, and the FDA and reviewed by the RAC at its next regularly scheduled meeting."

OMB's "Mandatory Information Requirements for Federal Assistance Program Announcements" (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally, NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers not only virtually every NIH program but also essentially every Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

Effective Date: March 1, 1996.

Harold Varmus,
Director, National Institutes of Health.

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Proposed Collection; Comment Request

In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Substance Abuse and Mental Health Services Administration will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call the SAMHSA Reports Clearance Office on (301) 443-0525.

Comments are invited on: (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Project: Drug And Alcohol Services Information System

—Revision—The DASIS consists of three related data systems: the National Facility Register, the Uniform Facility Data Set, and the Treatment Episode Data Set. Together, they provide information on the location, scope and characteristics of all known drug and alcohol treatment and prevention facilities in the United States, and the characteristics of clients receiving services. This information is needed to assess the nature and extent of these resources, to identify gaps in services, and to provide a database for treatment referrals. The FY 1996 DASIS was approved under OMB control number 0930-0168. This request is for continuation of DASIS with minor revisions to the data collection instruments. Automated data collection methods are employed by DASIS. The total annual burden estimate is 87,278 hours, as shown below:

<table>
<thead>
<tr>
<th>States</th>
<th>Facilities</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden per response (hours)</th>
<th>Total burden (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>56</td>
<td>19,400</td>
<td>591</td>
<td>2.386</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td>0.428</td>
<td></td>
</tr>
</tbody>
</table>

Send comments to Deborah Trunzo, SAMHSA Reports Clearance Officer, Room 16-105, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: March 6, 1996.

Richard Kopanda,
Acting Executive Officer, SAMHSA.

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[NV–931–1020–001]

Northeastern Great Basin Resource Advisory Council Meeting Locations and Times

AGENCY: Bureau of Land Management, Interior.

ACTION: Resource Advisory Councils' Meeting Locations and Times.

SUMMARY: In accordance with the Federal Land Policy and Management Act and the Federal Advisory Committee Act of 1972 (FACA), 5 U.S.C., the Department of the Interior, Bureau of Land Management (BLM), Council meetings will be held as indicated below. The agenda for each meeting includes approval of minutes of the previous meeting, continuation of Council orientation, discussion of Standards and Guidelines for management of the public lands within the jurisdiction of the Council and determination of the subject matter for future meetings.

All meetings are open to the public. The public may present written comments to the Council. Each formal Council meeting will also have time allocated for hearing public comments. The public comment period for three Council meetings is listed below. Depending on the number of persons wishing to comment and time available, the time for individual oral comments may be limited. Individuals who plan to attend and need further information about the meetings, or need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the District Manager at the Battle Mountain